Clinical Trial Update: Relation Between TOF-Watch® SX and a Peripheral Nerve Stimulator After 4.0 mg.Kg-1 Sugammadex (P05698) [Phase 3]

View source ↗

Summary

This Phase 3 clinical trial assesses how readings from the TOF-Watch SX peripheral nerve stimulator relate to a standard peripheral nerve stimulator after admin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuromuscular Blockade

Drugs mentioned

• Sugammadex (sugammadex)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Neuromuscular Blockade | Phase 3 | Status: COMPLETED | Results posted: 2013-09-02